312 related articles for article (PubMed ID: 25630625)
1. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Chowdhary SA; Ryken T; Newton HB
J Neurooncol; 2015 Apr; 122(2):367-82. PubMed ID: 25630625
[TBL] [Abstract][Full Text] [Related]
2. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
3. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
[TBL] [Abstract][Full Text] [Related]
4. The role of Gliadel wafers in the treatment of high-grade gliomas.
Bregy A; Shah AH; Diaz MV; Pierce HE; Ames PL; Diaz D; Komotar RJ
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1453-61. PubMed ID: 24236823
[TBL] [Abstract][Full Text] [Related]
5. Implantation of carmustine wafers (Gliadel
Champeaux C; Weller J
J Neurooncol; 2020 Mar; 147(1):159-169. PubMed ID: 31974802
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M;
Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422
[TBL] [Abstract][Full Text] [Related]
7. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Xing WK; Shao C; Qi ZY; Yang C; Wang Z
Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
[TBL] [Abstract][Full Text] [Related]
8. Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Champeaux-Depond C; Jecko V; Weller J; Constantinou P; Tuppin P; Metellus P
J Neurooncol; 2023 Apr; 162(2):343-352. PubMed ID: 36991304
[TBL] [Abstract][Full Text] [Related]
9. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
10. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Nagpal S
Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
[TBL] [Abstract][Full Text] [Related]
11. Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Champeaux-Depond C; Jecko V; Weller J; Constantinou P; Tuppin P; Metellus P
World Neurosurg; 2023 May; 173():e778-e786. PubMed ID: 36906091
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy wafers for high grade glioma.
Hart MG; Grant R; Garside R; Rogers G; Somerville M; Stein K
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD007294. PubMed ID: 21412902
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
14. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Barr JG; Grundy PL
Br J Neurosurg; 2012 Dec; 26(6):818-22. PubMed ID: 22715955
[TBL] [Abstract][Full Text] [Related]
15. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Sai K; Zhong MG; Wang J; Chen YS; Mou YG; Ke C; Zhang XH; Yang QY; Lin FH; Guo CC; Chen ZH; Zeng J; Lv YC; Li X; Gao WC; Chen ZP
J Neurol Sci; 2014 Aug; 343(1-2):60-5. PubMed ID: 24874252
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
20. Cerebral edema associated with Gliadel wafers: two case studies.
Weber EL; Goebel EA
Neuro Oncol; 2005 Jan; 7(1):84-9. PubMed ID: 15701285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]